MET Activating Mutation
2 clinical trials · Condition
◉ Watch MET Activating Mutation
| Record | Firm | Date |
|---|---|---|
| Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer (NCT07153770) | Shanghai Pulmonary Hospital, Shanghai, China | 2025-09-20 |
| Study of Crizotinib for ROS1 and MET Activated Lung Cancer (NCT04084717) | University Health Network, Toronto | 2019-12-03 |
Track MET Activating Mutation automatically
Every clearance here is in the API, with alerts when new ones post.